» Articles » PMID: 8061451

Comparative Signal Intensity Measurements in Dynamic Gadolinium-enhanced MR Mammography

Overview
Date 1994 May 1
PMID 8061451
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Increases in signal intensity enhancement were measured in defined regions of interest (ROIs) to allow distinction between malignant and benign tumors with dynamic gadolinium-enhanced magnetic resonance (MR) mammography. Twenty patients with palpable breast lesions (15 malignant, five benign) underwent MR mammography. The dynamic gradient-echo sequence was performed with intravenous bolus injection of gadopentetate dimeglumine and consisted of 25 images with a time resolution of 30 seconds. Contrast enhancement was calculated by comparing user-defined ROIs on pre- and postcontrast images. An increase in signal intensity of 70% or more on the 1-minute postcontrast image was used as the criterion of malignancy. MR mammographic results correlated with histopathologic findings in all patients when the defined ROI was in the most enhancing part of the tumor. For the ROI in areas of submaximal enhancement or when the ROI surrounded the whole lesion, only five and nine tumors, respectively, fulfilled the malignancy criterion. All malignant tumors showed large variations in signal intensity enhancement that depended on the position of the ROI in the tumor. Dynamic, gadolinium-enhanced MR mammography allows distinction of benign from malignant breast tumors when the selected ROI is in the most enhancing part of the lesion.

Citing Articles

Correcting time-intensity curves in dynamic contrast-enhanced breast MRI for inhomogeneous excitation fields at 7T.

van Rijssel M, Pluim J, Chan H, van den Wildenberg L, Schmitz A, Luijten P Magn Reson Med. 2019; 84(2):1000-1010.

PMID: 31880346 PMC: 7217168. DOI: 10.1002/mrm.28147.


Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients.

H M van der Velden B, Sutton E, Carbonaro L, Pijnappel R, Morris E, Gilhuijs K Eur Radiol. 2018; 28(11):4705-4716.

PMID: 29736850 PMC: 6182741. DOI: 10.1007/s00330-018-5470-7.


Novel PCA-VIP scheme for ranking MRI protocols and identifying computer-extracted MRI measurements associated with central gland and peripheral zone prostate tumors.

Ginsburg S, Viswanath S, Bloch B, Rofsky N, Genega E, Lenkinski R J Magn Reson Imaging. 2014; 41(5):1383-93.

PMID: 24943647 PMC: 8176951. DOI: 10.1002/jmri.24676.


Semi-quantitative parameter analysis of DCE-MRI revisited: monte-carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis.

Jackson A, Li K, Zhu X PLoS One. 2014; 9(3):e90300.

PMID: 24594707 PMC: 3942428. DOI: 10.1371/journal.pone.0090300.


Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.

Yang X, Knopp M J Biomed Biotechnol. 2011; 2011:732848.

PMID: 21541193 PMC: 3085501. DOI: 10.1155/2011/732848.